Literature DB >> 8896410

A deletion mutation causes hemophilia B in Lhasa Apso dogs.

A E Mauser1, J Whitlark, K M Whitney, C D Lothrop.   

Abstract

Hemophilia B is a bleeding disorder caused by a deficiency of clotting factor IX (FIX). A colony of FIX deficient Lhasa Apso dogs has been established and the molecular basis of hemophilia B has been determined. The plasma factor IX levels were < 1% of normal canine levels in affected dogs. A complex deletion mutation at nucleotides 772-777 was found when hepatocyte cDNA from a hemophilia B dog was sequenced. The sequence was identical to the normal canine sequence except for a deletion including nucleotides 772-776 and a C-->T transition at nucleotide 777. The mutation results in mRNA instability and a premature termination codon in the nucleotide sequence encoding the activation peptide. The mutation was verified by sequencing genomic DNA from an FIX-deficient dog. A genetic test for the detection of heterozygous animals was established using heteroduplex analysis. Although hemophilia B has been described in many dog breeds, this is only the second mutation to be sequenced. The Lhasa Apso dog model should be valuable for evaluating novel strategies for treating hemophilia B such as gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8896410

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

Review 1.  Gene therapy for the hemophilias.

Authors:  M A Kay; K High
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 2.  Adeno-associated virus-mediated gene transfer for hemophilia B.

Authors:  Katherine A High
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 3.  Semper fidelis: what man's best friend can teach us about human biology and disease.

Authors:  E A Ostrander; E Giniger
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

4.  Web resource on available DNA variant tests for hereditary diseases and genetic predispositions in dogs and cats: An Update.

Authors:  Jennifer L Rokhsar; Julia Canino; Karthik Raj; Scott Yuhnke; Jeffrey Slutsky; Urs Giger
Journal:  Hum Genet       Date:  2021-02-06       Impact factor: 4.132

Review 5.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

6.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

Authors:  Glenn P Niemeyer; Roland W Herzog; Jane Mount; Valder R Arruda; D Michael Tillson; John Hathcock; Frederik W van Ginkel; Katherine A High; Clinton D Lothrop
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

7.  From caveman companion to medical innovator: genomic insights into the origin and evolution of domestic dogs.

Authors:  Heidi G Parker; Samuel F Gilbert
Journal:  Adv Genomics Genet       Date:  2015-06-12

8.  AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.

Authors:  Julie M Crudele; Jonathan D Finn; Joshua I Siner; Nicholas B Martin; Glenn P Niemeyer; Shangzhen Zhou; Federico Mingozzi; Clinton D Lothrop; Valder R Arruda
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

9.  The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Authors:  Jay N Lozier; Amalia Dutra; Evgenia Pak; Nan Zhou; Zhili Zheng; Timothy C Nichols; Dwight A Bellinger; Marjorie Read; Richard A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

Review 10.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.